PMID- 38116329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231221
IS  - 2451-9936 (Electronic)
IS  - 2451-9936 (Linking)
VI  - 33
DP  - 2024 Mar
TI  - Two cases of diabetic macular edema with diminished areas of retinal 
      non-perfusion and microaneurysms after intravitreal faricimab injections.
PG  - 101973
LID - 10.1016/j.ajoc.2023.101973 [doi]
LID - 101973
AB  - PURPOSE: To report two cases of diabetic macular edema (DME) treated with 
      intravitreal faricimab injections (IVFs), including the assessment of retinal 
      microaneurysms and extent of retinal capillary non-perfusion using fluorescein 
      angiography (FA) and indocyanine green angiography (IA). OBSERVATIONS: Case 1: A 
      72-year-old man presented with aflibercept-resistant DME in the left eye, with a 
      best-corrected visual acuity (BCVA) of 20/16. FA showed areas of retinal 
      capillary non-perfusion and focal leakage in the macular area of the left eye. IA 
      revealed numerous microaneurysms in the temporal region of the macula. Four 
      consecutive monthly IVFs were administered to the left eye, and DME eventually 
      diminished. After the loading phase, the BCVA was maintained at 20/16 with 
      reduced visual distortion. FA showed improvement of macular leakage and stable 
      retinal capillary non-perfusion areas, and the foveal avascular zone was clearly 
      observed. The disappearance of numerous microaneurysms was confirmed on IA 
      images.Case 2: An 80-year-old woman developed DME with macular vein occlusion in 
      the left eye after panretinal laser photocoagulation for proliferative diabetic 
      retinopathy. The patient's BCVA was 20/32. DME was resistant to subtenon 
      triamcinolone injections. FA revealed focal areas of retinal capillary 
      non-perfusion and persistent leakage in the macular area of the left eye. IA 
      revealed scattered microaneurysms within the retinal arcade. Four consecutive 
      monthly IVFs were administered to the left eye, and DME eventually diminished. 
      After the loading phase, the BCVA was maintained at 20/32. FA showed improvement 
      of macular leakage and stable retinal capillary non-perfusion areas. The 
      reduction of microaneurysms was confirmed on IA images. CONCLUSIONS AND 
      IMPORTANCE: These case reports highlight the potential of faricimab as an 
      alternative anti-vascular endothelial growth factor drug for treatment-resistant 
      DME, including reduction of retinal microaneurysms and stabilization of the areas 
      of retinal capillary non-perfusion. However, continuation of a robust treatment 
      regimen may be required to achieve these objectives.
CI  - (c) 2023 The Authors.
FAU - Sawa, Miki
AU  - Sawa M
AD  - Eye Center, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, 
      Osaka, Japan.
FAU - Nakagawa, Norihiko
AU  - Nakagawa N
AD  - Eye Center, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, 
      Osaka, Japan.
FAU - Shunto, Takuya
AU  - Shunto T
AD  - Eye Center, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, 
      Osaka, Japan.
FAU - Nishiyama, Issei
AU  - Nishiyama I
AD  - Eye Center, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, 
      Osaka, Japan.
LA  - eng
PT  - Case Reports
DEP - 20231207
PL  - United States
TA  - Am J Ophthalmol Case Rep
JT  - American journal of ophthalmology case reports
JID - 101679941
PMC - PMC10727933
OTO - NOTNLM
OT  - Diabetic macular edema
OT  - Fluorescein angiography
OT  - Indocyanine angiography
OT  - Intravitreal anti-vascular endothelial growth factor
OT  - Intravitreal faricimab injection
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/12/20 06:43
MHDA- 2023/12/20 06:44
PMCR- 2023/12/07
CRDT- 2023/12/20 03:59
PHST- 2023/08/01 00:00 [received]
PHST- 2023/11/17 00:00 [revised]
PHST- 2023/12/01 00:00 [accepted]
PHST- 2023/12/20 06:44 [medline]
PHST- 2023/12/20 06:43 [pubmed]
PHST- 2023/12/20 03:59 [entrez]
PHST- 2023/12/07 00:00 [pmc-release]
AID - S2451-9936(23)00181-0 [pii]
AID - 101973 [pii]
AID - 10.1016/j.ajoc.2023.101973 [doi]
PST - epublish
SO  - Am J Ophthalmol Case Rep. 2023 Dec 7;33:101973. doi: 10.1016/j.ajoc.2023.101973. 
      eCollection 2024 Mar.